The Clot Thickens

Hidradenitis suppurativa (HS) treatment and melanoma management protocols dominate this clinical discussion. Povercitinib, an oral JAK1 inhibitor, demonstrates statistically significant efficacy in phase 3 trials for HS, showing improved outcomes over 54 weeks despite a modest separation from placebo and manageable safety concerns regarding zoster and acne. Regarding melanoma, recent data challenges NCCN guidelines, suggesting that sentinel lymph node biopsies may be unnecessary for transected T1A lesions, as studies show zero positive nodes in these cases. Furthermore, the discussion addresses the hypercoagulability risks associated with JAK inhibitors, proposing a disease-specific mechanism where NF-kappa B activation and IL-10 signaling create a pro-thrombotic environment in conditions like rheumatoid arthritis, while suggesting these risks may not translate to dermatological conditions like alopecia areata or vitiligo.